ストックスクリーナーアプリを入手
0.92
4.37%
-0.0212
アフターアワーズ：
.90
-0.02
-2.17%
前日終値:
$0.9412
開ける：
$0.9411
24時間の取引高:
201.95K
Relative Volume:
0.80
時価総額：
$38.78M
収益：
-
当期純損益:
$-81.22M
株価収益率:
-0.2997
EPS:
-3.07
ネットキャッシュフロー:
$-74.41M
1週間 パフォーマンス:
-5.98%
1か月 パフォーマンス:
+11.23%
6か月 パフォーマンス:
-24.99%
1年 パフォーマンス:
-18.17%
1日の値動き範囲:
$0.851
$0.9411
1週間の範囲:
$0.81
$1.10
52週間の値動き範囲:
$0.49
$1.93
Xilio Therapeutics Inc Stock (XLO) Company Profile
XLO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| XLO | 0.92 | 38.78M | 0 | -81.22M | -74.41M | -3.07 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-21 | 開始されました | Chardan Capital Markets | Buy |
| 2022-01-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-16 | 開始されました | Cowen | Outperform |
| 2021-11-16 | 開始されました | Guggenheim | Buy |
| 2021-11-16 | 開始されました | Morgan Stanley | Overweight |
| 2021-11-16 | 開始されました | Raymond James | Outperform |
すべてを表示
Xilio Therapeutics Inc (XLO) 最新ニュース
Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World
Xilio Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Xilio Therapeutics Inc. (XLO) Quarterly 10-Q Report - Quartzy
Xilio to present new cancer treatment data at SITC - Investing.com
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz
Xilio Therapeutics Announces Initial Clinical Trial Data - GlobeNewswire
Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan
Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St
Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com
XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com
XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com
XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily
Market Resilience: XTI Aerospace Inc. (XTIA) Finishes Weak at 0.22, Down -4.06 - The Dwinnex
Tencent-Backed AI Drug Researcher Xtalpi’s Shares Double On Revenue Rise - Forbes Africa
Xilio Therapeutics Inc (XLO)’s highs and lows: A closer look at its stock price fluctuations - US Post News
(XFLT) Trading Signals - Stock Traders Daily
Balance Sheet Breakdown: Xilio Therapeutics Inc (XLO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
There’s evidence fragile X symptoms can be reduced with an experimental drug - KUOW News and Information
Slew of New Drugs Sends Xencor Shares Soaring - Los Angeles Business Journal
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World
XTX Topco Ltd Has $2.01 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
XLO Stock Sees Decline of Approximately -10.26% in Last Five Days - Knox Daily
Analytical Lens: Exploring Xilio Therapeutics Inc (XLO)’s Financial Story Through Ratios - The Dwinnex
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire
Xilio Therapeutics shares hold Buy rating on clinical trial focus - Investing.com
Xilio Therapeutics shares hold Buy rating on clinical trial focus By Investing.com - Investing.com Canada
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results - GlobeNewswire
Understanding the Risks of Investing in Xilio Therapeutics Inc (XLO) - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Simply Wall St
Head to Head Analysis: Indivior (NASDAQ:INDV) versus Xilio Therapeutics (NASDAQ:XLO) - Defense World
Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth? - Yahoo Finance
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Drops By 83.1% - Defense World
$82 million series A round propels Exsilio into gene editing race - The Pharma Letter
Head to Head Analysis: Xilio Therapeutics (NASDAQ:XLO) versus VBI Vaccines (NASDAQ:VBIV) - Defense World
Biopharma Layoff Tracker 2024: Ginkgo, Cara, Barinthus and More Cut Staff - BioSpace
Xilio Therapeutics Inc (XLO) stock analysis: A comprehensive overview – US Post News - US Post News
Investing in Xilio Therapeutics Inc (XLO): What You Must Know – Knox Daily - Knox Daily
Xilio Therapeutics Inc (XLO)'s Market Momentum: Closing Strong at 0.95, Down -0.33 – DWinneX - The Dwinnex
Xilio Therapeutics, Inc. (NASDAQ:XLO) Shares Sold by Octagon Capital Advisors LP - Defense World
Xilio Therapeutics expands board with industry experts - Investing.com India
Xilio Therapeutics expands board with industry experts By Investing.com - Investing.com
Xilio Therapeutics Enhances Board with Two New DirectorsTipRanks.com - TipRanks
Xilio Therapeutics Inc (XLO) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):